Loading
A phase 2 trial of Trastuzumab brengitecan, Pertuzumab, Docetaxel in her2-positive breast cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.
A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer is a phase 2 interventional study registered as NCT06445400 by Sichuan Baili Pharmaceutical Co., Ltd., with 83 participants enrolled, started 2024-06-19 and due to reach its primary completion in 2025-07-21. Interventions recorded: BL-M07D1, Pertuzumab, Docetaxel. Conditions listed: HER2-positive Breast Cancer. No results are recorded here; the registry entry is the source.
Shares Trastuzumab brengitecan, Pertuzumab, SystImmune / Sichuan Biokin, Docetaxel.
Shares Trastuzumab brengitecan, Pertuzumab, SystImmune / Sichuan Biokin, Docetaxel.
Shares Trastuzumab brengitecan, SystImmune / Sichuan Biokin, HER2-positive breast cancer.
Shares Pertuzumab, Docetaxel, HER2-positive breast cancer, Monoclonal antibodies.
Shares Trastuzumab brengitecan, SystImmune / Sichuan Biokin, HER2-positive breast cancer.
Shares SystImmune / Sichuan Biokin, Docetaxel, Cytotoxic chemotherapy.
Shares Pertuzumab, HER2-positive breast cancer, Monoclonal antibodies.
Shares Pertuzumab, Docetaxel, HER2-positive breast cancer, Monoclonal antibodies.